Memory chip maker, Micron Technology, Inc. (NASDAQ:MU) dropped in last session as after it missing fiscal Q3 targets, pulling other chip stocks down with it. Boise, Idaho-based Micron late Thursday as well gave weak outlook for the present quarter. Micron CEO Mark Durcan stated in a statement that in the fiscal Q3, Micron experienced market headwinds driven primarily by weakness in the PC sector. At least eight Wall Street investment banks cut their price targets on Micron stock after the earnings report. Bernstein Research slashed its price target to 28 from 45, but reiterated its outperform rating. Credit Suisse trimmed its price target to 34 from 50, but kept its outperform rating. Jefferies cut its target to 36 from 40 and maintained its buy rating. Pacific Crest Securities lowered its target to 26 from 32 and stuck with its overweight rating. Micron Technology, Inc. (NASDAQ:MU) has the market capitalization of 21.11 Billion. Shares of firm moved down -18.15% to close at $19.66 with the total traded volume of 148.87 Million. The firm has current ratio of 2.40 for the most recent quarter.
Target Corp. (NYSE:TGT) declared that Kathryn Tesija, Executive VP and Chief Merchandising and Supply Chain Officer, will shift to a strategic advisory role on July 6, 2015. So, Tesija will no longer be secret as an executive officer following July 6, 2015. The firm articulated that Tesija has decided to remain employed by Target on an at-will basis until April 1, 2016 to help by means of the transition of her responsibilities and provide advisory services. In this new role, Ms. Tesija will persist to get her current base salary through April 1, 2016, and current target bonus opportunity for fiscal year 2015 performance. Following the conclusion of her employment she will be eligible for severance payments under Target’s Income Continuance Policy. Target Corp. (NYSE:TGT) stock price closed at $84.08 with the total traded volume of 6.19 Million shares. Its price to sales ratio ended at 0.73. Its market capitalization is 53.68 Billion. The stock owned by the Financial Institutions was 87.90% while by insiders was 0.10%.
Bristol-Myers Squibb Company (NYSE:BMY) released that firm aims to discontinue discovery research efforts in virology, reliable with the evolution of its R&D strategic focus, which was released in 2013. The firm reported that the Discovery organization will discontinue its research efforts in virology. This comprises early research in hepatitis B and HIV. About 100 Discovery positions will be abolished because of the changes. Bristol-Myers reported the decision does not impact its ongoing clinical development program in virology, nor does it impact the company’s marketed products in virology. Bristol-Myers Squibb Company (NYSE:BMY) begun last trade with a price of $67.04 and throughout the trading session climbed at a high of $67.68. The day-trade ended with 1.05% to $67.54. The stock is going forward to its 52 week low with 45.41% and lagging behind from its 52 week high price with -3.32%. BMY last month stock price volatility remained 1.90%.
